Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Anika Therapeutics (ANIK) Other Operating Expenses (2016 - 2021)

Historic Other Operating Expenses for Anika Therapeutics (ANIK) over the last 12 years, with Q4 2021 value amounting to $825000.0.

  • Anika Therapeutics' Other Operating Expenses rose 10526.95% to $825000.0 in Q4 2021 from the same period last year, while for Sep 2022 it was $825000.0, marking a year-over-year increase of 10847.28%. This contributed to the annual value of -$21.1 million for FY2021, which is 821.88% up from last year.
  • According to the latest figures from Q4 2021, Anika Therapeutics' Other Operating Expenses is $825000.0, which was up 10526.95% from -$3.4 million recorded in Q3 2021.
  • Over the past 5 years, Anika Therapeutics' Other Operating Expenses peaked at $8.7 million during Q4 2017, and registered a low of -$24.3 million during Q4 2018.
  • Moreover, its 5-year median value for Other Operating Expenses was $5.0 million (2019), whereas its average is $1.2 million.
  • As far as peak fluctuations go, Anika Therapeutics' Other Operating Expenses crashed by 1020000.0% in 2020, and later skyrocketed by 18473.02% in 2021.
  • Over the past 5 years, Anika Therapeutics' Other Operating Expenses (Quarter) stood at $8.7 million in 2017, then plummeted by 378.56% to -$24.3 million in 2018, then skyrocketed by 99.37% to -$152000.0 in 2019, then plummeted by 10200.0% to -$15.7 million in 2020, then surged by 105.27% to $825000.0 in 2021.
  • Its Other Operating Expenses was $825000.0 in Q4 2021, compared to -$3.4 million in Q3 2021 and $6.5 million in Q2 2021.